Scholarlink

Purpose <p>This review examines the role of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the pathogenesis of type 2 diabetes mellitus (T2DM) and evaluates its potential as a pharmacological target. The central question addressed is why selective 11β-HSD1 inhibitors produce robust metabolic improvements in preclinical models yet yield only modest glycemic benefit in human clinical trials, and how this gap might be overcome through patient stratification and precision medicine.</p> Methods <p>A structured literature search was conducted using the Scopus database. Articles were included only if they were also indexed in PubMed. Search terms combined 11β-HSD1 nomenclature with diabetes-related terms and thematic qualifiers covering pathophysiology, molecular mechanisms, tissue-specific involvement, gene expression, inflammation, and pharmacological inhibition. Retrieved studies were synthesized across molecular biology, experimental models, clinical evidence, medicinal chemistry, and future therapeutic directions.</p> Results <p>11β-HSD1 amplifies local glucocorticoid action in liver, adipose, skeletal muscle, and pancreas, driving hepatic glucose overproduction, adipose dysfunction, β-cell impairment, and insulin resistance. Knockout mice show 15–30% reductions in fasting glucose, while adipose-specific overexpression fully recapitulates metabolic syndrome. Clinical studies confirm elevated adipose 11β-HSD1 expression in T2DM, and HSD11B1 variants associate with increased diabetes risk. Four inhibitors : INCB-13739, MK-0916, AZD4017, and BI 187004 completed Phase II evaluation, producing HbA1c reductions of only 0.3–0.6%. BI 187004 achieved near-complete hepatic inhibition yet produced no clinically relevant glycemic improvement, demonstrating that target engagement alone is insufficient in unselected populations.</p> Conclusion <p>The preclinical-clinical gap reflects tachyphylaxis in human adipose tissue, compensatory HPA axis activation, and enrollment of heterogeneous patient populations rather than target invalidity. A precision medicine strategy enrolling patients with demonstrably elevated tissue-specific enzyme activity, combined with biomarker-guided selection and combination antidiabetic regimens, offers the most viable path forward. Beyond T2DM, 11β-HSD1 inhibition shows potential in nonalcoholic fatty liver disease, diabetic wound healing, and age-related metabolic decline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in 11-HSD1 Inhibitor Development for Addressing Insulin Resistance and Beta-Cell Dysfunction in Type 2 diabetes mellitus

  • 期刊论文

  • 发表日期：

    2026年3月28日

查看全文
  • Pallavi Joshi,
  • Avijit Mazumder,
  • Bhavani Pentela,
  • Abhijit Debnath

摘要

Purpose

This review examines the role of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the pathogenesis of type 2 diabetes mellitus (T2DM) and evaluates its potential as a pharmacological target. The central question addressed is why selective 11β-HSD1 inhibitors produce robust metabolic improvements in preclinical models yet yield only modest glycemic benefit in human clinical trials, and how this gap might be overcome through patient stratification and precision medicine.

Methods

A structured literature search was conducted using the Scopus database. Articles were included only if they were also indexed in PubMed. Search terms combined 11β-HSD1 nomenclature with diabetes-related terms and thematic qualifiers covering pathophysiology, molecular mechanisms, tissue-specific involvement, gene expression, inflammation, and pharmacological inhibition. Retrieved studies were synthesized across molecular biology, experimental models, clinical evidence, medicinal chemistry, and future therapeutic directions.

Results

11β-HSD1 amplifies local glucocorticoid action in liver, adipose, skeletal muscle, and pancreas, driving hepatic glucose overproduction, adipose dysfunction, β-cell impairment, and insulin resistance. Knockout mice show 15–30% reductions in fasting glucose, while adipose-specific overexpression fully recapitulates metabolic syndrome. Clinical studies confirm elevated adipose 11β-HSD1 expression in T2DM, and HSD11B1 variants associate with increased diabetes risk. Four inhibitors : INCB-13739, MK-0916, AZD4017, and BI 187004 completed Phase II evaluation, producing HbA1c reductions of only 0.3–0.6%. BI 187004 achieved near-complete hepatic inhibition yet produced no clinically relevant glycemic improvement, demonstrating that target engagement alone is insufficient in unselected populations.

Conclusion

The preclinical-clinical gap reflects tachyphylaxis in human adipose tissue, compensatory HPA axis activation, and enrollment of heterogeneous patient populations rather than target invalidity. A precision medicine strategy enrolling patients with demonstrably elevated tissue-specific enzyme activity, combined with biomarker-guided selection and combination antidiabetic regimens, offers the most viable path forward. Beyond T2DM, 11β-HSD1 inhibition shows potential in nonalcoholic fatty liver disease, diabetic wound healing, and age-related metabolic decline.